Trusted medical expertise in seconds.

Access 1,000+ clinical and preclinical articles. Find answers fast with the high-powered search feature and clinical tools.

Try free for 5 days
Evidence-based content, created and peer-reviewed by physicians. Read the disclaimer.

Infectious mononucleosis

Last updated: April 16, 2021

Summarytoggle arrow icon

Infectious mononucleosis (IM), also called "mono" or the "kissing disease", is an acute condition caused by the Epstein-Barr virus (EBV). The disease is highly contagious and spreads via bodily secretions, especially saliva. Infection frequently goes unnoticed in children; mainly adolescents and young adults exhibit symptoms. Symptomatic individuals typically first experience fever, malaise, and fatigue, which is later accompanied by acute pharyngitis, tonsillitis, lymphadenopathy, and/or splenomegaly lasting up to a month. IM is also sometimes associated with a measles-like exanthem, especially in individuals who are falsely diagnosed with bacterial tonsillitis and given ampicillin or amoxicillin. To avoid misdiagnosis, suspected cases are confirmed with a heterophile antibody test (monospot test), or in some cases, positive serology. Patients exhibit lymphocytosis, often with atypical T lymphocytes on a peripheral smear. IM is treated symptomatically, as it is usually self-limiting. Although complications are rare, IM is associated with atraumatic splenic rupture due to splenomegaly and multiple malignancies (e.g., Hodgkin's lymphoma, Burkitt lymphoma).

  • General: Approx. 90–95% of adults are EBV-seropositive worldwide. [1]
  • Peak incidence: (of symptomatic disease): 15–24 years of age [2]
  • Incidence: 5/1000 per year [3]

Epidemiological data refers to the US, unless otherwise specified.

  • Pathogen: Epstein-Barr virus (EBV), also called human herpesvirus 4 (HHV-4)
  • Transmission: : Infectious mononucleosis is highly contagious and spreads via bodily secretions, especially saliva. Therefore, it is also called kissing disease.

References:[4]

“You must Be (B lymphocytes) 21 (CD21) to drink in a BAR (Epstein-BARr virus).”

Splenomegaly can lead to a potentially life-threatening splenic rupture!

In most cases, a maculopapular rash occurs due to empiric administration of aminopenicillins, and not due to EBV infection.

Clinical suspicion of IM is confirmed via antibody testing.

Serology Past infection Primary infection
anti-VCA IgM negative positive
anti-VCA IgG positive positive
Anti-EBNA-1 IgG positive negative

Tonsillitis is an important differential diagnosis that is often treated with aminopenicillins (e.g., ampicillin). However, if given to a patient with IM, the patient often develops a macular erythematous rash after 5–9 days.

The differential diagnoses listed here are not exhaustive.

Therapy of IM is mainly symptomatic.

  • Avoid physical activity because of the risk of splenic rupture.
    • Patients should avoid strenuous physical activities for at least 21 days after initial symptoms develop. [13]
    • Patients should avoid high-contact sports (e.g., football, wrestling) for at least 4 weeks
  • Fluids (IV administration if necessary)
  • Analgesics/antipyretics (e.g., acetaminophen)
  • Steroids are not recommended for routine use but may be considered in complicated cases.

Immunocompromised patients have a higher risk of developing complications. [14]

We list the most important complications. The selection is not exhaustive.

  1. Houldcroft CJ, Kellam P. Host genetics of Epstein–Barr virus infection, latency and disease. Rev Med Virol. 2014; 25 (2): p.71-84. doi: 10.1002/rmv.1816 . | Open in Read by QxMD
  2. Jarrett RF. Risk factors for Hodgkin's lymphoma by EBV status and significance of detection of EBV genomes in serum of patients with EBV-associated Hodgkin's lymphoma.. Leuk Lymphoma. 2003; 44 Suppl 3 : p.S27-32. doi: 10.1080/10428190310001623801 . | Open in Read by QxMD
  3. González Saldaña N, Monroy Colín VA, Piña Ruiz G, Juárez Olguín H. Clinical and laboratory characteristics of infectious mononucleosis by Epstein-Barr virus in Mexican children.. BMC research notes. 2012; 5 : p.361. doi: 10.1186/1756-0500-5-361 . | Open in Read by QxMD
  4. Luzuriaga K, Sullivan JL. Infectious mononucleosis. N Engl J Med. 2010; 362 (21): p.1993-2000. doi: 10.1056/nejmcp1001116 . | Open in Read by QxMD
  5. Dunmire SK, Grimm JM, Schmeling DO, Balfour HH Jr, Hogquist KA. The Incubation Period of Primary Epstein-Barr Virus Infection: Viral Dynamics and Immunologic Events.. PLoS Pathog. 2015; 11 (12): p.e1005286. doi: 10.1371/journal.ppat.1005286 . | Open in Read by QxMD
  6. Incidence of rash after amoxicillin treatment in children with infectious mononucleosis. https://www.ncbi.nlm.nih.gov/pubmed/23589810. Updated: May 1, 2013. Accessed: March 17, 2017.
  7. Sangueza-Acosta M, Sandoval-Romero E. Epstein-Barr virus and skin.. An Bras Dermatol. 2018; 93 (6): p.786-799. doi: 10.1590/abd1806-4841.20187021 . | Open in Read by QxMD
  8. Rubin E, Reisner HM. Essentials of Rubin's Pathology. Lippincott Williams & Wilkins ; 2009
  9. Infectious mononucleosis: histopathologic aspects. https://www.ncbi.nlm.nih.gov/pubmed/170576. Updated: January 1, 1975. Accessed: March 17, 2017.
  10. Wright DH, Addis BJ, Leong ASY. Diagnostic Lymph Node Pathology. Hachette UK Company ; 2011
  11. Infectious mononucleosis. The spectrum of morphologic changes simulating lymphoma in lymph nodes and tonsils.. https://www.ncbi.nlm.nih.gov/pubmed/3812872. Updated: February 1, 1987. Accessed: March 17, 2017.
  12. Mononucleosis-Like Syndrome. http://www.fpnotebook.com/id/virus/MnclsLkSyndrm.htm. Updated: March 3, 2017. Accessed: March 17, 2017.
  13. Becker JA, Smith JA. Return to play after infectious mononucleosis.. Sports health. 2014; 6 (3): p.232-8. doi: 10.1177/1941738114521984 . | Open in Read by QxMD
  14. Epstein-Barr Virus and Infectious Mononucleoisis. https://www.cdc.gov/epstein-barr/hcp.html. Updated: September 14, 2016. Accessed: March 28, 2017.
  15. Bar-Or A, Pender MP, Khanna R, et al. Epstein–Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies. Trends Mol Med. 2019; 26 (3): p.296-310. doi: 10.1016/j.molmed.2019.11.003 . | Open in Read by QxMD
  16. Larroche C. Hemophagocytic lymphohistiocytosis in adults: diagnosis and treatment.. Joint bone spine. 2012; 79 (4): p.356-61. doi: 10.1016/j.jbspin.2011.10.015 . | Open in Read by QxMD
  17. Oliveira C, Chacim S, Ferreira I, Domingues N, Mariz JM. Secondary Hemophagocytic Syndrome: The Importance of Clinical Suspicion. Case Reports in Hematology. 2014; 2014 : p.1-5. doi: 10.1155/2014/958425 . | Open in Read by QxMD
  18. Pannone G, Zamparese R, Pace M, et al. The role of EBV in the pathogenesis of Burkitt’s Lymphoma: an Italian hospital based survey. Infect Agent Cancer. 2014; 9 (1): p.34. doi: 10.1186/1750-9378-9-34 . | Open in Read by QxMD
  19. Auwaerter PG. Patient education: Infectious mononucleosis (mono) in adults and adolescents (Beyond the Basics). In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. http://www.uptodate.com/contents/infectious-mononucleosis-mono-in-adults-and-adolescents-beyond-the-basics.Last updated: June 15, 2015. Accessed: March 17, 2017.
  20. Sullivan JL. Clinical manifestations and treatment of Epstein-Barr virus infection. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. https://www.uptodate.com/contents/clinical-manifestations-and-treatment-of-epstein-barr-virus-infection?source=machineLearning&search=EBV&selectedTitle=1~150§ionRank=1&anchor=H25#H25.Last updated: May 4, 2015. Accessed: March 17, 2017.